Zymeworks Current Ratio 2016-2022 | ZYME
Zymeworks current ratio from 2016 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Zymeworks Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-06-30 |
$0.26B |
$0.08B |
3.29 |
| 2022-03-31 |
$0.32B |
$0.08B |
4.05 |
| 2021-12-31 |
$0.29B |
$0.07B |
4.01 |
| 2021-09-30 |
$0.34B |
$0.08B |
4.47 |
| 2021-06-30 |
$0.39B |
$0.08B |
4.73 |
| 2021-03-31 |
$0.43B |
$0.07B |
6.16 |
| 2020-12-31 |
$0.46B |
$0.09B |
5.31 |
| 2020-09-30 |
$0.49B |
$0.10B |
5.03 |
| 2020-06-30 |
$0.47B |
$0.07B |
6.48 |
| 2020-03-31 |
$0.51B |
$0.07B |
6.92 |
| 2019-12-31 |
$0.31B |
$0.08B |
3.78 |
| 2019-09-30 |
$0.35B |
$0.05B |
6.81 |
| 2019-06-30 |
$0.37B |
$0.04B |
9.07 |
| 2019-03-31 |
$0.19B |
$0.03B |
6.76 |
| 2018-12-31 |
$0.20B |
$0.03B |
6.82 |
| 2018-09-30 |
$0.15B |
$0.02B |
6.42 |
| 2018-06-30 |
$0.17B |
$0.02B |
7.26 |
| 2018-03-31 |
$0.07B |
$0.02B |
4.09 |
| 2017-12-31 |
$0.09B |
$0.02B |
6.30 |
| 2017-09-30 |
$0.05B |
$0.01B |
4.57 |
| 2017-06-30 |
$0.07B |
$0.01B |
5.60 |
| 2017-03-31 |
$0.03B |
$0.02B |
1.57 |
| 2016-12-31 |
$0.05B |
$0.02B |
2.81 |
| 2016-09-30 |
$0.00B |
|
0.00 |
| 2016-06-30 |
$0.00B |
|
0.00 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-12-31 |
$0.02B |
$0.01B |
3.64 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.519B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
